



ANNUAL GENERAL MEETING

22 NOVEMBER 2017

CHAIRMAN'S ADDRESS

Dear Fellow Shareholders

Welcome to Viralytics' 2017 Annual General Meeting.

The momentum Viralytics built in 2016 continued to accelerate strongly into the current year under review.

The company's diligent and focused scientific endeavours, led by Dr McColl and Professor Darren Shafren, have cemented Viralytics' position as one of the leading oncolytic virus companies in the field today.

Our lead drug candidate, CAVATAK[®], is performing well, and we are quietly confident of its prospects, as the clinical data from our multiple trials continue to mature.

Earlier this month we presented further positive clinical and pre-clinical data at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in National Harbor MD in the United States. In June at the prestigious world cancer conference, the American Society for Clinical Oncology (ASCO), held in Chicago, Viralytics achieved the rare distinction for an ASX biotech of being chosen for a prominent podium presentation from among more than 5,000 international exhibitors.

Our partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) remains on a solid foundation with promising, albeit very early, data on our collaborative KEYNOTE-200 study presented at SITC. At the same time we continue to maintain dialogue and extend our networks with other major pharmaceutical players.

Viralytics remains well funded, with strong support from some of the industry's leading life science venture funds to pursue our vision for the CAVATAK technology.

The year ahead promises to be very exciting, with planning well advanced for studies in new indications. Interest in oncolytic viruses as an important new cancer immunotherapy approach remains high.



On behalf of the Board, I thank the management team for their outstanding contribution during the year, and you, our shareholders, for your continued support.

Paul A. Hopper

Chairman